RE:RE:RE:RE:RE:RE:RE:My dream is A high profile bright CFO would not in my mind have made an agreement with CF so much ahead of drawing on the ATM without getting something back early after the agreement.....Dont know if CF is legally prohibited ftom initiating coverage but if this is thr case the ATM agreement probably negates any hope of eventually getting paid for a deal by another broker who would initiatiate coverage ....
Removing that incentive wad an unnecessary hurdle. !!'!!! Self inflicted wounds again !!!
Wino115 wrote: More than anything, I think this shows that Akero is now looked
at as a serious NASH player -they've made it to that status so NASH
analysts pick it up to be "thorough" in their coverage.
Probably also hit various market cap & trading hurdles.
I am hopeful that if we see POC on TH1902 and they get
Breakthrough & Accellerated and a financial model can be built
around their indications and commercial program (plus any
partnerships they add) that supports a robust investment
thesis, that they too will be looked at as a serious oncology
player that needs to be covered by biotech and oncology
analysts.
For a starter, I would think anyone who covers (covered) IMMU,
SeaGen or Bicycle should cover THTX. Those kind of pickups
with no banking carrot being held out indicate you've made it to
the bigtime with the analysts.